Predictors of relapse rate in MS clinical trials

Neurology

Volumn 65, Issue 11, 2005, Pages 1769-1773

  Held, U ^a   Heigenhauser, L ^a   Shang, C ^a   Kappos, L ^b   Polman, C ^c  

^a Sylvia Lawry Centre for Multiple Sclerosis Research   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; PLACEBO;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PHASE 3 CLINICAL TRIAL; POISSON DISTRIBUTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; AGE; CENTRAL NERVOUS SYSTEM; DISABILITY; EPIDEMIOLOGY; FEMALE; MALE; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; RECURRENT DISEASE; REGRESSION ANALYSIS; SEX DIFFERENCE; STATISTICAL MODEL; STATISTICS;

AGE FACTORS; AGE OF ONSET; CAUSALITY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIALS; DISABILITY EVALUATION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MODELS, STATISTICAL; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; REGRESSION ANALYSIS; SEX FACTORS;

EID: 33645054350     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000187122.71735.1f     Document Type: Article

References (23)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
2. Jacobs LD, Cookfair DL, Rudick RA, et al., the Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
3. PRISMS (Prevention of Relapses and disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
4. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497.
5. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology 2001;56:1496-1504.
6. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-1276.
7. Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244:153-159.
8. Hartung HP, Gonsette R, König N, et al., and the Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-2025.
9. Fazekas F, Deisenhammer F, Strasser Fuchs, S, et al., for the Austrian Immunoglobulin in Multiple Sclerosis Study Group. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997;349:589-593.
10. Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998;50:398-402.
11. Weinshenker BG, Ebers GC. The natural history of multiple sclerosis. Can J Neurol Sci 1987;14:255-261.
12. Ebers G. Natural history of multiple sclerosis. In: Compston A, Ebers G, Lassmann H, McDonald WI, Matthews B, Wekerle H, eds. McAlpine's multiple sclerosis, 3rd ed. London: Churchill Livingstone, 1998;191-222.
13. Goodkin DE, Hertsgaard D, Rudick RA. Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. Arch Neurol 1989;46:1107-1112.
14. Rovaris M, Comi G, Ladkani D, Wolinsky JS, Filippi M. European/Canadian Glatiramer Acetate Study Group. Short-term correlations between clinical and MR imagine findings in relapsing-remitting multiple sclerosis. AM J Neuroradiol 2003;24:75-81.
15. Paty DW. The interferon-β1b clinical trial and its implications for other trials. Ann Neurol 1994;36:113-114.
16. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995;13:119-146.
17. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999;353:964-969.
18. Fahrmeir L, Tutz G. Multivariate statistical modelling based on generalized linear models, 2nd ed. New York: Springer, 2001.
19. Venables WN, Ripley BD. Modern applied statistics with S-Plus, 3rd ed. New York: Springer, 1999.
20. Barkhof F, Filippi M, Miller DH, Tofts P, Kappos L, Thompson AJ. Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. J Neurol 1997;244:76-84.
21. Molyneux PD, Filippi M, Barkof F, et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis: a multi-centre longitudinal study. Ann Neurol 1998;43:332-339.
22. Caramanos Z, Santos AC, Arnold DL. Magnetic resonance imaging and spectroscopy: Insights into the pathology and pathophysiology of multiple sclerosis. In: McDonald WI, Noseworthy JH, eds. Multiple sclerosis 2. Philadelphia: Butterworth-Heinemann, 2003;139-167.
23. Kappos L, Duda P. The Janus face of CNS-directed autoimmune response: a therapeutic challenge (Editorial). Brain 2002;125:2379-2380.